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SUMMARY: In agr ement with prior studies, we show that non-typhoidal Salmonella 
is prevalent in stool of children under the age of 5, albeit at low levels, in Africa and 
South Asia and that Salmonella Typhimurium ST313 can be carried 





















BACKGROUND: The Global Enteric Multicenter Study (GEMS) determined the 
etiologic agents of moderate-to-severe diarrhea (MSD) in children under 5 years old 
in Africa and Asia. Here, we describe the prevalence and antimicrobial susceptibility 
of non-typhoidal Salmonella (NTS) serovars in GEMS and examine the 
phylogenetics of Salmonella Typhimurium ST313 isolates. 
METHODS: Salmonella isolated from children with MSD or diarrhea-free controls 
were identified by classical clinical microbiology and serotyped using antisera and/or 
whole genome sequence data. We evaluated antimicrobial susceptibility using the 
Kirby-Bauer disk diffusion method. Salmonella Typhimurium sequence types were 
determined using multi-locus sequence typing and whole genome sequencing was 
performed to assess the phylogeny of ST313.  
RESULTS: Out of 370 Salmonella-positive individuals, 190 (51.4%) were MSD 
cases and 180 (48.6%) were diarrhea-free controls. The most frequent Salmonella 
serovars identified were Salmonella Typhimurium, serogroup O:8 (C2-C3), serogroup 
O:6,7 (C1), Salmonella Paratyphi B Java and serogroup O:4 (B). The prevalence of 
NTS was low but similar across sites, regardless of age, and was similar amongst 
both cases and controls except in Kenya, where Salmonella Typhimurium was more 
commonly associated with cases than controls. Phylogenetic analysis showed that 
these Salmonella Typhimurium isolates, all ST313, were highly genetically related to 
isolates from controls. Generally, Salmonella isolates from Asia were resistant to 




















CONCLUSION: Our data confirms that NTS is prevalent, albeit at low levels, in 
Africa and South Asia. Our findings provide further evidence that multi-drug resistant 
Salmonella Typhimurium ST313 can be carried asymptomatically by humans in sub-
Saharan Africa. 
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Salmonella enterica subspecies enterica serovars Typhi (Typhi), Paratyphi A 
(Paratyphi A) and Paratyphi B sensu stricto (Paratyphi B) cause enteric fever, while 
non-typhoidal Salmonella (NTS) generally cause self-limited gastroenteritis in 
healthy individuals. However, in young infants, the elderly and immunocompromised 
hosts, NTS can lead to bacteremia resulting in hospitalization and death [1]. In some 
resource-limited countries, NTS is a recognized etiologic agent of diarrhea [2-5] and 
an important risk factor for diarrhea-related morbidity and mortality in children [6]. In 
2015, an estimated 37,410 children died as a result of NTS gastroenteritis; with a 
large burden of disease in Southeast Asia and South Asia [7]. Serovars Typhimurium 
and Enteritidis are the most common NTS isolated from cases of gastroenteritis 
worldwide. Despite the capacity to isolate Salmonella by stool culture, little is known 
about the prevalence of NTS serovars that cause gastroenteritis in Africa and South 
Asia.  
Invasive NTS (iNTS) causes bacteremia in sub-Saharan Africa, occurring 
predominantly in infants, toddlers, as well as in HIV-infected, malnourished and/or 
malaria-infected adults [8, 9]. Although the incidence of iNTS has declined in many 
sites across Africa [10], it is still one of the most common causes of bloodstream 
infections in African children [11]. Interestingly, unique clades of serovars 
Typhimurium and Enteritidis are associated with bacteremia in this region [8, 12, 13]. 
Most of the Typhimurium strains isolated from blood in sub-Saharan Africa belong to 
multi-locus sequence type (ST) 313 [14]. In contrast, the most common genotype 
isolated worldwide is ST19 which is generally associated with gastroenteritis [15] but 
has recently been reported as a primary cause of invasive infections in a study in 



















either gastroenteritis or bacteremia in Kenya, although the number of diarrhea cases 
was low [17]. 
The use of antibiotics to treat uncomplicated NTS gastroenteritis in children is 
not recommended, except where progression to invasive disease is a risk [18, 19]. 
However, information about the antimicrobial susceptibility of NTS is useful as this 
knowledge contributes to our overall understanding of resistance markers that are 
circulating in specific geographic locations. In fact, NTS harboring antimicrobial 
resistance traits in the gastrointestinal tract could serve as a reservoir for iNTS [20]. 
Presently, countries with the highest burden of iNTS disease report 48-75% 
multidrug resistance (MDR) to commonly-used antibiotics; a major concern given 
that more effective 3rd generation cephalosporins or fluoroquinolones may be less 
available or more costly in these settings [11, 21].  
During 2007–2010, the Global Enteric Multicenter Study (GEMS) determined 
the etiologic agents of moderate-to-severe diarrhea (MSD) in children 0-59 months 
old living in The Gambia, Mali, Mozambique, Kenya, India, Bangladesh and Pakistan 
[22]. This large, prospective, case-control study determined that NTS was 
significantly associated with MSD in infants (0-11 months) from the Bangladesh site 
and toddlers (12-23 m) and young children (24-59 m) from the Kenya site [22]. Here, 
we determined the prevalence of Salmonella serovars isolated in GEMS, evaluated 
antimicrobial susceptibility, identified Typhimurium sequence types, and examined 





















GEMS study participants 
The methods and main findings from GEMS have previously been described 
[22-24]. Briefly, GEMS participants were recruited from censused populations during 
2007-2010 in The Gambia, Mali, Mozambique, Kenya, Bangladesh, India and 
Pakistan. Study participants included children aged 0-59 months of age with MSD 
who presented to a sentinel health facility (see Supplementary text for additional 
details). Children were recruited into 0-11-, 12-23- and 24-59-month age groups. For 
each child with MSD (case) enrolled, 1-3 children without diarrhea during the 
previous week (controls) were recruited. Scientific and ethical committees and 
Institutional Review Boards (IRBs) of participating institutions in each country as well 
as the coordinating institution, University of Maryland, Baltimore, approved the study 
protocol prior to implementation. Informed consent was obtained in the local dialect 
from all participating caretakers before recruitment of their children into the study.  
 
Detection of Salmonella spp. 
A panel of enteropathogens was identified from stool specimens, collected at 
the clinic from MSD cases or obtained at home by caregivers of children in the 
control group, as previously described [24]. Salmonella spp. were shipped to the 
Center for Vaccine Development and Global Health (CVD) at the University of 




















Characterization of Salmonella serovars from stools 
At CVD, Salmonella spp. were agglutinated using polyvalent O and O1 
antisera followed by serogroups O:2 (A), O:4 (B), O:6,7 and O:7 (C1), O:6,8 and O:8 
(C2-C3), O:9 (D1), O:9,46 (D2), O:3,10 (E1), O:11 (F), O:13 (G) antisera (Denka 
Seiken, Tokyo, Japan). Serovars Typhimurium, Typhi, Enteritidis and Paratyphi B 
were fully serotyped (using O and H typing antisera) and additionally confirmed by 
PCR [25, 26].  
 
Sequence typing of Typhimurium isolates 
Sequence types were determined for all 87 Typhimurium isolates using Multi-
Locus Sequence Typing (MLST) by PCR and sequencing and/or by examining whole 
genome sequences. Sequence typing by MLST followed methodology described 
previously [15].  
 
Whole genome sequencing and phylogenetic analysis 
The majority of the Salmonella isolates (355 out of 370) were subjected to 
whole genome sequencing (WGS). Following sequencing, 120 isolates were 
excluded from subsequent analyses as they did not meet the quality control criteria. 





















Antimicrobial susceptibility testing 
The susceptibility of the 370 Salmonella isolates to chloramphenicol, 
ampicillin, ciprofloxacin, trimethoprim/sulfamethoxazole (TMP/SMX), gentamicin and 
ceftriaxone was determined using the Kirby-Bauer disk diffusion method and 
interpreted according to Clinical and Laboratory Standards Institute (CLSI) 
guidelines. Multidrug resistance (MDR) was defined as resistance to ampicillin, 
chloramphenicol and TMP/SMX. To assess whether the high resistance of NTS to 
antimicrobials was associated with antibiotic prescription rate, we determined the 
percentage of children with MSD (and Salmonella isolated in stools) who had been 
prescribed (but may or may not have been given) antimicrobial agents after visiting 
any of the sentinel health facilities that participated in GEMS. 
 
Statistical analysis 
To determine which individual Salmonella serovars were driving the 
association between Salmonella and MSD that was found in the original GEMS 
analyses [22], we used the same conditional logistic regression model as previously 
described [27]. Instead of including Salmonella species in the model we included 
variables for each Salmonella serogroup/serovar [18, 33]. The association of each 
serovar with MSD was adjusted for other co-pathogens (Supplementary Table 2). 
The rationale for this approach, generally, and in the unique context of GEMS, has 
been discussed previously [27]. Analyses were conducted using R version 3.3.2. P-





















Characteristics of MSD study participants 
Of the cases with Salmonella identified, 86 (44%) were in the 0-11 m age 
group, 55 (29%) were in the 12-23 m age group and 49 (26%) were in the 24-59 m 
age group (Table 1). Cases experienced severe signs of MSD. Approximately 20% 
of infants with Salmonella spp. detected had bloody diarrhea, while 100% of children 
12-to 59-months-old with Salmonella spp. produced watery diarrhea. Of note, a 
lower proportion of children with MSD who had Salmonella isolated tended to be 
female in all age groups. 
 
Geographical distribution and prevalence of Salmonella serovars  
The serovar distribution of the 370 Salmonella isolates (190 from cases and 
180 from controls) collected from stools of study participants is shown in Figure 1. Of 
these, 361 were NTS. Additionally, we recovered eight Typhi from Asia and one 
Paratyphi A isolate from Bangladesh. The most frequent NTS serovars identified 
were Typhimurium, serogroup O:8 (C2-C3), serogroup O:6,7 (C1), Paratyphi B Java 
and serogroup O:4 (other than Typhimurium or Paratyphi B). Serovar Typhimurium 
predominated in Africa, whereas serogroup O:6,7 (C1) and O:8 (C2-C3) serovars 




















Prevalence of Salmonella serovars by site and age stratum 
The prevalence of the most abundant serovars isolated in GEMS, as well as 
serovar Enteritidis (due to its importance in iNTS disease in Africa), are shown in 
Table 2. The individual serovars of isolates are listed in Supplementary Table 1. In 
general, we found that the rates of NTS isolation were low (≤ 5.3%) in both cases 
and controls regardless of age groups, although some site-to-site variation was 
apparent. At the Kenya site, serovar Typhimurium, the most prevalent serovar, was 
recovered in stools of MSD cases at a rate of 3.3% for infants, 3.7% for toddlers and 
4.3% for young children. In Bangladesh, Paratyphi B Java, the most prevalent 
serovar there, was recovered from 2.0% of infants with MSD. Serogroup O:8 (C2-C3) 
organisms were most prevalent in stools at the Pakistan site. The prevalence of NTS 
in cases and controls in The Gambia, Mali, Mozambique and India was less than 
1.5%.  
 
Salmonella serovars significantly associated with MSD  
Previously, 3.2% and 3.7% of MSD episodes in toddlers (12-23 m) and 
children (24-59 m) at the Kenya site, respectively, and 4.6% of MSD episodes in 
infants at the Bangladesh site were shown to be attributable to Salmonella [22]. We 
determined the serovars driving the associations by using a conditional logistic 
regression model (Supplementary Table 2). In Bangladesh, serogroup O:6,7 (C1) 
(Odd’s Ratio [OR] = 6.4, 95% CI = 1.84-22.58), O:8 (C2-C3) (OR = 6.0, 95% CI = 
1.28-28.33) and serovar Paratyphi B Java (OR = 4.8, 95% CI = 1.87-12.29) were 
significantly associated with MSD. In Kenya, the association was driven by serovar 



















59 m (OR = 4.9, 95% CI = 2.09-11.64). All other serovars occurred in too few cases 
and controls to produce significant results.  
 
Antimicrobial susceptibility at GEMS sites 
Salmonella isolates from the African and Asian sites differed in terms of their 
antimicrobial susceptibility (Figure 2). Isolates from Africa were susceptible to 
ciprofloxacin and ceftriaxone whereas resistance to these antibiotics was observed 
amongst Asian NTS isolates. We observed 65.4% of NTS from MSD cases in Kenya 
to be multidrug resistant (MDR) to ampicillin, trimethoprim/sulfamethoxazole 
(TMP/SMX) and chloramphenicol. However, isolation of non-susceptible NTS was 
less frequent at The Gambian site; only 6.7% of NTS from cases showed an MDR 
phenotype (Figure 2A). In Asia, Indian isolates showed more resistance to the 
antibiotics tested than isolates from the other two Asian sites (Figure 2B). We 
observed similar antimicrobial susceptibility profiles amongst NTS from controls as 
from cases at each site except for Kenya and India.  
Serovars Typhimurium and Enteritidis from Africa and serogroup O:6,7 (C1) 
and serogroup O:13 (G) isolates from Asia showed the highest percentage of 
antimicrobial resistance (Figure 3). All Enteritidis and Paratyphi B Java isolates 
recovered from GEMS stools from Asia were pan-susceptible to antimicrobial 
agents, while the six serogroup O:13 (G) isolates from Africa were pan-susceptible. 



















In general, most MSD cases with Salmonella had been prescribed or given an 
antibiotic (except in Pakistan) (Table 3). TMP/SMX was the most commonly 
prescribed antibiotic in Africa whereas ciprofloxacin was the most common in Asia.  
 
Phylogenetic analysis of Salmonella Typhimurium 
Since Typhimurium was the most important cause of iNTS disease at several 
GEMS sites and was the most frequent serovar isolated from stools, a phylogenetic 
analysis was performed. Of 87 Typhimurium isolates, 74 (85.0%) were from Africa 
(Kenya), while 13 (14.9%) were from Asia (Pakistan, India and Bangladesh). Table 4 
shows the sequence types (ST) of these Typhimurium isolates listed by site of origin.  
A phylogeny was constructed using whole genome sequences to determine 
the relationship between the Typhimurium ST313 isolates from MSD cases and 
controls (Figure 4). The African ST313 sequence type has been divided into the 
older lineage 1 isolates, and the more recent lineage 2 [13, 28]. Here, 50 of 55 study 
isolates analyzed (90.9%) clustered with the ST313 lineage 2 reference genome 
D23580, 49 of 55 (89%) of which showed the typical MDR phenotype associated 
with lineage 2, namely resistance to chloramphenicol, co-trimoxazole and ampicillin. 
The lineage 2 isolates from the MSD cases and diarrhea-free controls were closely 
related and could not be distinguished phylogenetically. A group of 5 isolates in 
stools of cases and controls, regardless of age, formed a small lineage 2 sub-cluster 
associated with susceptibility to chloramphenicol.  
Four of the 55 isolates (7%) clustered with the ST313 lineage 1 reference 
genome A130, all of which were isolated from MSD cases in Kenya and were 



















failed to cluster with lineage 1 or lineage 2 and demonstrated pan-susceptibility to 
antibiotics was isolated from a case of MSD from Pakistan.  
 
DISCUSSION 
Salmonella isolates were detected in stools of children with MSD and from 
diarrhea-free community controls at each of the GEMS sites. A primary finding of our 
analysis was that except for Typhimurium, the prevalence of most Salmonella 
serovars was similar in stools of cases and controls, regardless of age and across 
study sites. Because children enrolled as controls in GEMS only had to have been 
free of diarrhea for the previous seven days, we could not rule out asymptomatic 
carriage or shedding of Salmonella among controls due to persistent excretion or 
convalescence [29]. NTS are reportedly excreted for longer periods in children than 
adults, lasting from several weeks to months [18, 30]. We found that NTS was as 
prevalent in cases as in controls, which suggests that NTS is endemic at the seven 
GEMS sites [3, 31, 32].  
In this study, we report the association of Typhimurium ST313 with acute 
diarrhea in Kenya using a conditional logistic regression model, showing that these 
bacteria cause diarrhea and are not just associated with invasive disease. This 
observation is supported by recent studies from Kenya, Central African Republic and 
Democratic Republic of Congo which also detected Typhimurium ST313 in stool [17, 
33, 34]. Typhimurium ST313 was identified in both MSD cases and controls, 
confirming that this important sequence type can be carried asymptomatically by 
humans. Phylogenetic analysis identified lineages 1 and 2, in accordance with 



















prevalent in the stools of both MSD cases and controls. The fact that isolates from 
cases and controls are found in every part of the phylogeny suggests that the 
Typhimurium that cause MSD are closely related to those associated with 
asymptomatic carriage; NTS carriage has been reported elsewhere in sub-Saharan 
Africa [34-36].  
Several groups have attempted to identify the reservoir of iNTS isolates in 
Africa. Kariuki et al [20] were the first to suggest that iNTS are not acquired 
zoonotically, but are acquired by anthroponotic transmission. In this and other 
studies, NTS isolated from blood cultures of bacteremic index cases were highly 
similar to isolates from household contacts but different from NTS from animal or 
environmental sources taken from around the homes of index cases [20, 36]. 
Collectively, these prior studies suggest that the reservoir for Typhimurium ST313 is 
indeed humans. It remains possible the lack of detection of Salmonella spp. from 
animals and the environment reflects difficulties in culture from these specimen 
types. However, if the inference from the above-mentioned studies is correct, our 
data would support these findings by showing that Typhimurium strains isolated from 
stool of cases and controls in GEMS are highly genetically related to isolates from 
blood.  
When we examined antimicrobial susceptibility of GEMS NTS isolates, we 
detected marked regional differences in resistance. We observed similar 
antimicrobial susceptibility patterns in stools of cases and asymptomatic controls at 
all GEMS sites except Kenya and India. Our data suggest that antibiotic resistant 
NTS are circulating in the GEMS communities. Non-susceptible NTS strains could 
serve as a reservoir from which antibiotic resistance determinants can spread 



















Enteritidis isolates were MDR which is consistent with previous findings [20, 38]. 
Importantly, none of the isolates from GEMS African sites were resistant to 
ciprofloxacin or ceftriaxone in contrast to isolates from Asia, suggesting a difference 
in utilization of these antibiotics. Five (of 8) Typhi from India and Pakistan were MDR 
but none were extensively drug resistant (XDR) as seen in the recent typhoid fever 
outbreak in Hyderabad, Pakistan [39].  
Antibiotics are not recommended for treatment of NTS gastroenteritis in 
pediatric patients due to the predisposition for extended excretion of bacteria and 
relapse of infection [18, 40, 41]. However, our data suggest that children with NTS 
disease are being prescribed antibiotics, which may have selected for resistant 
bacteria. We observed high prescription rates for ciprofloxacin and other 
fluoroquinolones in Asia and not surprisingly, also high resistance of Salmonella to 
ciprofloxacin in Asia, but not Africa (where ciprofloxacin was rarely prescribed). In 
contrast, we recorded high antibiotic prescription rates of TMP/SMX in Africa which 
possibly led to the high resistance observed in Africa. TMP/SMX in combination with 
highly active antiretroviral therapy (HAART) has been used routinely as prophylaxis 
for opportunistic infections in patients with HIV in Africa [42].  
The low frequency of Salmonella in MSD cases from Mali, The Gambia and 
Mozambique was somewhat unexpected given that these countries report high iNTS 
disease burdens [3, 31, 32]. However, the incidence of iNTS disease during GEMS 
(2007-2010) in these three countries decreased relative to earlier estimates, 
concomitant with a reduction in clinical malaria [3, 31, 32, 43]. Indeed, there is 
growing evidence to suggest that iNTS disease is correlated with clinical malaria and 



















44]. A re-analysis of GEMS using quantitative molecular diagnostic methods showed 
higher attributable fractions for Salmonella in all age groups at all sites [45].  
Our findings have three main implications: 1) the prevalence data could be 
used to refine incidence estimates for individual Salmonella serovars; 2) we report 
for the first time the association of Typhimurium ST313 with acute diarrhea, thereby 
showing that these bacteria are not just associated with invasive disease; and 3) our 
data demonstrates wide-spread asymptomatic carriage of ST313, a key cause of 
iNTS infections. Because we have found that humans are carriers of MDR 
Salmonella strains that also cause iNTS [46], it is possible that these individuals 
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Table 1. Characteristics of children with moderate-to-severe diarrhea (MSD) and from 
whom Salmonella were isolated 
Clinical signs and symptomsa 0-11 m (n=86) 12-23 m (n=55) 24-59 m (n=49) 
Stool consistency 
   Mucus 72.94% 61.82% 53.06% 
Pus 3.49% 9.09% 12.24% 
Bloody 24.42% 12.73% 0 
Watery 75.58% 87.27% 100 
Medical history 
   Vomiting >3 times/day 40.70% 40.0% 48.98% 
Drank much less than usual 19.77% 21.82% 14.29% 
Very thirsty 59.3% 67.27% 83.33% 
Decreased activity or lethargy 36.05% 54.55% 53.06% 
Irritable or restless 45.35% 61.82% 55.10% 
Fever >38C or parent perception 73.26% 72.73% 77.55% 
Physical examination 
   Admitted to the hospital 17.44% 18.18% 22.45% 



















Loss of skin turgor 26.74% 25.45% 36.73% 
Dry mouth 54.65% 74.55% 81.63% 
Sunken eyes 65.12% 85.45% 87.76% 
Axillary temperature >38.3C 18.60% 21.82% 26.53% 
Gender 




































Kolkata, India Mirzapur, 
Bangladesh 
Karachi (Bin Qasim 
Town), Pakistan 
Prevalence of NTS Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls 
0-11 months               
No. of participants 400 585 727 727 374 697 673 673 672 685 550 878 633 633 
No. of NTS 5 (1.3%) 12 
(2.1%) 


















Typhimurium 0 0 0 0 0 0 22 
(3.3%) 




0 1 (0.2%) 1 (0.2%) 
Enteritidis 0 0 0 0 1 
(0.3%) 
0 2 (0.3%) 2 (0.3%) 0 0 0 0 0 0 
Paratyphi B 
Java 




8 (0.9%) 1 (0.2%) 0 
Serogroup O:4 0 0 0 0 0  1 
(0.1%) 




0 2 (0.3%) 2 (0.3%) 
Serogroup O:6,7  1 (0.3%) 2 (0.3%) 0 0 0 0 3 (0.4%) 3 (0.4%) 0 0 9 
(1.6%) 
4 (0.5%) 4 (0.6%) 4 (0.6%) 
Serogroup O:8 0 1 (0.2%) 0 0 1 
(0.3%) 






1 (0.1%) 7 (1.1%) 13 
(2.1%) 
Other serovars 4 (1.0%) 9 (1.5%) 0 0 2 
(0.5%) 
0 3 (0.4%) 6 (0.9%) 0 5 
(0.7%) 
0 1 (0.1%) 0 4 (0.6%) 
12-23 months               
No. of participants 455 639 682 695 195 391 410 621 588 598 476 761 399 676 
















Typhimurium 0 0 0 0 0 0 15 
(3.7%) 
6 (1.0%) 0 0 2 
(0.4%) 
1 (0.1%) 1 (0.3%) 3 (0.4%) 
Enteritidis 0 0 0 0 0 0 4 (1.0%) 2 (0.3%) 0 0 2 
(0.4%) 
0 1 (0.3%) 1 (0.1%) 
Paratyphi B 
Java 
0 0 0 0 0 0 0 0 0 0 3 
(0.6%) 
2 (0.3%) 0 0 
Serogroup O:4 1 (0.2%) 0 1 (0.1%) 0 1 
(0.5%) 
0 1 (0.2%) 3 (0.5%) 0 0 0 1 (0.1%) 2 (0.5%) 2 (0.3%) 




0 1 (0.1%) 0 4 (0.6%) 
Serogroup O:8 1 (0.2%) 1 (0.2%) 0 0 0 0 3 (0.7%) 4 (0.6%) 0 1 
(0.2%) 
0 4 (0.5%) 4 (1.0%) 7 (1.0%) 
Other serovars 2 (0.4%) 3 (0.5%) 0 0 0 0 1 (0.2%) 4 (0.6%) 0 0 0 0 6 (1.5%) 2 (0.3%) 
24-59 months               
No. of participants 174 345 624 642 112 208 393 589 308 731 368 826 226 529 














Typhimurium 0 0 0 0 0 0 17 
(4.3%) 
5 (0.8%) 0 0 0 0 0 1 (0.2%) 
Enteritidis 0 0 0 0 0 0 1 (0.3%) 1 (0.2%) 0 0 1 
(0.3%) 




















0 0 0 0 0 0 0 0 0 0 2 
(0.5%) 
2 (0.2%) 0 0 
Serogroup O:4 0 0 1 (0.2%) 0 0 0 1 (0.3%) 0 0 0 0 0 1 (0.4%) 3 (0.6%) 






2 (0.2%) 2 (0.9%) 1 (0.2%) 
Serogroup O:8 0 0 0 0 0 0 0 2 (0.3%) 0 0 0 0 3 (1.3%) 1 (0.2%) 




2 (0.2%) 4 (3.1%) 4 (1.1%) 
Total participants 
(all ages) 
1029 1569 2033 2064 681 1296 1476 1883 1568 2014 1394 2465 1258 1838 













































Table 3. Proportion of children with MSD and positive for Salmonella prescribed any antimicrobial agents after 
seeking care at sentinel health facilities (SHF) that participated in GEMS at sites in Africa and Asia 
Antimicrobial agent
a
 Africa The Gambia Mali Mozambique Kenya Asia India Bangladesh Pakistan 
No. of cases
b
 100 15 2 5 78 90 5 42 43 
No antibiotics prescribed 
/ given 
23 (23.0%)  4 (26.7%) 0 0 19 (24.4%) 36 (40.0%) 0 1 (2.4%) 35 (81.4%) 
Any antibiotics 
prescribed / given 
77 (77.0%) 11 (73.3%) 2 (100%) 5 (100%) 59 (75.6%) 54 (60.0%) 5 (100%) 41 (97.6%) 8 (18.6%) 
Ampicillin 1 (1.0%) 0 0 1 (20.0%) 0 0 0 0 0 
Chloramphenicol 6 (6.0%) 3 (20.0%) 0 3 (60.0%) 0 0 0 0 0 
Ciprofloxacin/ other 
fluoroquinolone 
5 (5.0%) 1 (6.7%) 0 0 4 (5.1%) 43 (47.8%) 4 (80.0%) 31 (73.8%) 8 (18.6%) 
Trimethoprim 
/Sulfamethoxazole 
59 (59.0%) 8 (53.3%) 2 (100%) 1 (20.0%) 48 (61.5%) 6 (6.7%) 1 (20.0%) 5 (11.9%) 0 
Gentamicin 12 (12.0%) 0 0 2 (40.0%) 10 (12.8%) 0 0 0 0 
Amoxicillin 4 (4.0%) 1 (6.7%) 0 1 (20.0%) 2 (2.6%) 0 0 0 0 


















Erythromycin 1 (1.0%) 0 0 0 1 (1.3%) 1 (1.1%) 0 1 (2.4%) 0 
Penicillin 9 (9.0%) 0 0 2 (40.0%) 7 (9.0%) 0 0 0 0 
Selexid / Pivmecillinam 0 0 0 0 0 0 0 0 0 




antimicrobial agents that were tested for susceptibility 
b 



















Table 4. The sequence types (ST) of Typhimurium isolates identified in GEMS 
stools were determined using MLST PCR and/or whole genome sequencing 
 
Site Sequence type Total 
  ST36 ST313  
Africa 0 74 74 
Kenya 0 74 74 
Asia 9 4 13 
Bangladesh 4 0 4 
Pakistan 3 4 7 
India 2 0 2 






















Figure 1. Distribution of Salmonella serogroups and serovars isolated from MSD cases 
and diarrhea-free asymptomatic controls. Salmonella spp. isolated from stools at A) all 
seven GEMS sites, B) Africa and C) Asia. 
Figure 2. Percent of NTS non-susceptible to any of six commonly used antimicrobial 
agents. NTS isolated from A) Africa and B) Asia. NTS, non-typhoidal Salmonella; CIP, 
ciprofloxacin; CRO, ceftriaxone; GEN, gentamicin; CHL, chloramphenicol; AMP, 
ampicillin; TMP/SMX, trimethoprim/sulfamethoxazole; MDR, multidrug resistant. 
Figure 3. Percent of NTS that were non-susceptible to six antibiotics by serotype or 
serogroup. Only serotypes or serogroups that showed non-susceptibility to antibiotics 
are shown. NTS, non-typhoidal Salmonella; CIP, ciprofloxacin; CRO, ceftriaxone; GEN, 
gentamicin; CHL, chloramphenicol; AMP, ampicillin; TMP/SMX, 
trimethoprim/sulfamethoxazole; MDR, multidrug resistant. 
Figure 4. Genetic relationship between Salmonella Typhimurium ST313 isolated from 
MSD cases and diarrhoea-free controls. The core genome maximum likelihood tree is 
shown for Salmonella Typhimurium ST313 isolated from the stool of cases and controls 
of children aged under 5 years in Kenya and Pakistan (one isolate) which were 
collected as part of the GEMS study. Scale bars in Single Nucleotide Polymorphisms 
(SNPs) are shown beneath the phylogeny. Patient group, age range and antimicrobial 
resistance (AMR) data for the isolates are displayed using color strips created on ITOL 
and are labelled and coloured according to the inlaid key. Isolates which cluster with the 
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